Private company

NGM Biopharmaceuticals (United States)

American pharmaceutical preparations company based in South San Francisco.¹

Last updated Oct 18, 2026.

Overview

Jan 1, 2007Founded¹

IndustryPharmaceutical Preparations¹
HeadquartersSouth San Francisco¹
Websitewww.ngmbio.com
Legal formDelaware corporation¹
Incorporated inDE³
Business address333 Oyster Point Boulevard, South San Francisco, Ca 94080³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-3429.1%Operating margin⁴

-3223.3%Net margin⁴

-92.0%Revenue growth, 2023⁴

-95.8%Return on equity⁴

Where the money goes

Where each dollar of revenue went, fiscal 2023

Research and development

Research and development100¢$118.0M

Out of $4.4M in revenue.⁴ The company lost money this year.

Financial statements

Revenue⁵⁶⁷⁸⁴$4.4M in 2023−94% since 2017

Operating income⁵⁶⁷⁸⁴-$151.5M in 2023+769% since 2017

Net income⁵⁶⁷⁸⁴-$142.4M in 2023+906% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023
Revenue	$77.1M⁵	$108.7M⁶	$103.5M⁷	$87.4M⁸	$77.9M⁴	$55.3M⁴	$4.4M⁴
Research and development	$79.7M⁵	$95.7M⁶	$129.3M⁷	$164.0M⁸	$161.7M⁴	$181.1M⁴	$118.0M⁴
Operating income	-$17.4M⁵	-$4.3M⁶	-$49.3M⁷	-$103.8M⁸	-$120.7M⁴	-$166.2M⁴	-$151.5M⁴
Income tax	-$1.1M⁵	$0⁵	$0⁵
Net income	-$14.2M⁵	-$493.0K⁶	-$42.8M⁷	-$102.5M⁸	-$120.3M⁴	-$162.7M⁴	-$142.4M⁴
Earnings per share			-$0.85⁷	-$1.50⁸	-$1.56⁴	-$2.03⁴	-$1.73⁴
Earnings per share (diluted)			-$0.85⁷	-$1.50⁸	-$1.56⁴	-$2.03⁴	-$1.73⁴

Total assets⁵⁶⁷⁸⁴$168.9M in 2023−31% since 2018

Total liabilities⁵⁶⁷⁸⁴$20.2M in 2023−66% since 2018

Shareholders’ equity⁶⁷⁸⁴$148.6M in 2023

Cash⁵⁶⁷⁸⁴$55.8M in 2023+118% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023
Cash	$25.6M⁵	$56.9M⁵	$245.6M⁶	$147.0M⁷	$151.8M⁸	$73.5M⁴	$55.8M⁴
Current assets		$214.6M⁵	$355.2M⁶	$308.4M⁷	$379.3M⁸	$288.9M⁴	$156.4M⁴
Total assets		$246.1M⁵	$380.4M⁶	$329.0M⁷	$402.4M⁸	$307.4M⁴	$168.9M⁴
Current liabilities		$41.5M⁵	$39.7M⁶	$42.6M⁷	$61.4M⁸	$47.8M⁴	$20.1M⁴
Total liabilities		$59.4M⁵	$49.7M⁶	$49.0M⁷	$66.7M⁸	$47.8M⁴	$20.2M⁴
Shareholders’ equity	-$121.0M⁶	-$108.2M⁷	$330.7M⁸	$280.0M⁴	$335.6M⁴	$259.6M⁴	$148.6M⁴
Shares outstanding		6.9M shares⁵	67.0M shares⁶	70.6M shares⁷	78.0M shares⁸	81.9M shares⁴	82.9M shares⁴

Cash from operations⁵⁶⁷⁸⁴-$132.2M in 2023+659% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023
Cash from operations	-$17.4M⁵	-$7.6M⁶	-$41.2M⁷	-$83.5M⁸	-$73.2M⁴	-$144.4M⁴	-$132.2M⁴
Share buybacks		$185.0K⁶

Compare NGM Biopharmaceuticals (United States) with another company

Leadership

Who has led NGM Biopharmaceuticals (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

David J. Woodhouse2019–2024

Chair

William Jl Rieflin2019–2022

President

Chief financial officer

Chief operating officer

Aetna Wun Trombley2019–2020

2010201520202025

Chief executive officerDavid J. Woodhouse Apr 3, 2019 to Apr 8, 2024¹¹
ChairWilliam Jl Rieflin Apr 3, 2019 to Mar 4, 2022¹²
PresidentMangini Siobhan Nolan Jul 1, 2022 to Mar 6, 2023¹³
PresidentAetna Wun Trombley Apr 3, 2019 to Feb 6, 2020¹⁴
Chief financial officerJean-Frederic Viret Nov 8, 2023 to Apr 8, 2024¹⁵
Chief financial officerMangini Siobhan Nolan Jul 15, 2020 to Mar 6, 2023¹⁶
Chief financial officerDavid J. Woodhouse Apr 3, 2019 to Feb 6, 2020¹¹
Chief operating officerAetna Wun Trombley Apr 3, 2019 to Feb 6, 2020¹⁴

Board members and other officers (15)

Principal Accounting OfficerIrene Perlich Sep 18, 2023 to Apr 8, 2024¹⁷
SVP, GC & CCOValerie L. Pierce Mar 10, 2021 to Apr 8, 2024¹⁸
SVP, Chief Medical OfficerHsiao Lieu Apr 14, 2020 to Apr 8, 2024¹⁹
Chief Scientific OfficerJin-Long Chen Apr 3, 2019 to Mar 6, 2023²⁰
Board memberWilliam Jl Rieflin May 12, 2023 to Apr 8, 2024²¹
Board memberRoger M. Perlmutter Jun 10, 2021 to Apr 8, 2024²²
Board memberCarole Ho Jun 9, 2020 to Apr 8, 2024²³
Board memberDavid Goeddel V. Apr 3, 2019 to Apr 8, 2024²⁴
Board memberDavid J. Woodhouse Apr 3, 2019 to Apr 8, 2024¹¹
Board memberJin-Long Chen Apr 3, 2019 to Mar 6, 2023²⁰
Board memberMark Leschly Apr 3, 2019 to Jun 10, 2021²⁵
Board memberMcHenry T. Tichenor Apr 3, 2019 to May 22, 2020²⁶
Board memberPeter Svennilson Apr 3, 2019 to Apr 9, 2020²⁷
Board memberSuzanne Sawochka Hooper Apr 3, 2019 to Apr 8, 2024²⁸
Board memberShelly D. Guyer Dec 5, 2019 to Apr 8, 2024²⁹

Timeline

Apr 3, 2019New chief executive David J. Woodhouse becomes CEO¹¹
Jan 1, 2007Founded Founded¹

Filings

221 filings to the SEC since October 2021: 7 annual reports, 9 quarterly reports, 28 major events, 134 insider forms, 10 large holders, 33 other. The latest 20:

Apr 15, 202415-12G EDGAR
Apr 8, 2024EFFECT EDGAR
Apr 8, 20244 EDGAR
Apr 8, 20244 EDGAR
Apr 8, 20244 EDGAR
Apr 8, 20244 EDGAR
Apr 8, 20244 EDGAR
Apr 8, 20244 EDGAR
Apr 8, 20244 EDGAR
Apr 8, 20244 EDGAR
Apr 8, 20244 EDGAR
Apr 8, 20244 EDGAR
Apr 8, 20244 OWNERSHIP DOCUMENT EDGAR
Apr 8, 20244 OWNERSHIP DOCUMENT EDGAR
Apr 8, 20244 OWNERSHIP DOCUMENT EDGAR
Apr 8, 20244 OWNERSHIP DOCUMENT EDGAR
Apr 5, 2024S-8 POS EDGAR
Apr 5, 2024S-8 POS EDGAR
Apr 5, 2024S-8 POS EDGAR
Apr 5, 2024S-8 POS EDGAR

The 221 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 10 such filings since October 2021:

Apr 5, 2024SC 13D/A
Feb 26, 2024SC 13D/A
Feb 14, 2024SC 13G/A
Feb 13, 2024SC 13G/A
Dec 29, 2023SC 13D/A
Feb 13, 2023SC 13G/A
Feb 9, 2023SC 13G
Oct 28, 2022SC 13G
Jun 10, 2022SC 13D/A
Feb 3, 2022SC 13D/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataNGM Biopharmaceuticals (United States) on Wikidata
2
SEC EDGARNGM Biopharmaceuticals (United States) filings on SEC EDGAR
3
SEC EDGARNGM Biopharmaceuticals (United States) filings on SEC EDGAR
4
SEC EDGARNGM Biopharmaceuticals (United States) 10-K for fiscal 2023
5
SEC EDGARNGM Biopharmaceuticals (United States) 10-K for fiscal 2017
6
SEC EDGARNGM Biopharmaceuticals (United States) 10-K for fiscal 2018
7
SEC EDGARNGM Biopharmaceuticals (United States) 10-K for fiscal 2019
8
SEC EDGARNGM Biopharmaceuticals (United States) 10-K for fiscal 2020
9
SEC EDGARNGM Biopharmaceuticals (United States) 10-Q for fiscal 2023
10
SEC EDGARNGM Biopharmaceuticals (United States) 10-Q for fiscal 2023
11
SEC EDGARDavid J. Woodhouse, Chief executive officer
12
SEC EDGARWilliam Jl Rieflin, Chair
13
SEC EDGARMangini Siobhan Nolan, President
14
SEC EDGARAetna Wun Trombley, President
15
SEC EDGARJean-Frederic Viret, Chief financial officer
16
SEC EDGARMangini Siobhan Nolan, Chief financial officer
17
SEC EDGARIrene Perlich, Principal Accounting Officer
18
SEC EDGARValerie L. Pierce, SVP, GC & CCO
19
SEC EDGARHsiao Lieu, SVP, Chief Medical Officer
20
SEC EDGARJin-Long Chen, Chief Scientific Officer
21
SEC EDGARWilliam Jl Rieflin, Board member
22
SEC EDGARRoger M. Perlmutter, Board member
23
SEC EDGARCarole Ho, Board member
24
SEC EDGARDavid Goeddel V., Board member
25
SEC EDGARMark Leschly, Board member
26
SEC EDGARMcHenry T. Tichenor, Board member
27
SEC EDGARPeter Svennilson, Board member
28
SEC EDGARSuzanne Sawochka Hooper, Board member
29
SEC EDGARShelly D. Guyer, Board member